Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accretion NutravedaBOM:544694 21 EBITDA Margin % is 18.81% as of Mar. 2026, which is 24% below its 10-year median of 24.74. GuruFocus rates BOM:544694 with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 961 Drug Manufacturers companies, Accretion Nutraveda ranks better than 69.51% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Accretion Nutraveda EBITDA Margin % Related Terms
Accretion Nutraveda EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Accretion Nutraveda's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Nutraveda EBITDA Margin % Chart
Accretion Nutraveda Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
EBITDA Margin %
26.17
27.93
23.31
20.85
Accretion Nutraveda Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
Mar26
EBITDA Margin %
0.00
0.00
23.77
23.37
18.81
BOM:544694 vs ZTS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Accretion Nutraveda's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Nutraveda EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Nutraveda's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Accretion Nutraveda's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Nutraveda (BOM:544694) has a EBITDA Margin % of 18.81% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Accretion Nutraveda and its competitors. This is 24% below median its historical median of 24.74. Over the past decade, Accretion Nutraveda's EBITDA Margin % has ranged from 20.72 to 27.93. According to the industry distribution chart, Accretion Nutraveda ranks #293 out of 961 companies in the Drug Manufacturers industry, placing it in the top 30.5%.
Is Accretion Nutraveda's EBITDA Margin % too high?
Accretion Nutraveda's current EBITDA Margin % of 18.81% is 24% below median its 10-year median of 24.74. Over the past 10 years, this metric has ranged from a low of 20.72 to a high of 27.93. The Drug Manufacturers industry median EBITDA Margin % is 12.45. Accretion Nutraveda's value of 18.81% is 51.1% above this industry median. Based on the distribution chart, Accretion Nutraveda ranks #293 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Accretion Nutraveda has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Nutraveda's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Accretion Nutraveda ranks #293 out of 961 companies for EBITDA Margin %. This puts Accretion Nutraveda in the upper half of its industry. The industry median EBITDA Margin % is 12.45. Accretion Nutraveda's value of 18.81% is 51.1% above this benchmark. Historically, Accretion Nutraveda's own EBITDA Margin % has ranged from 20.72 to 27.93 over the past decade. While the company's 10-year median is 24.74 vs. the industry median of 12.45, Accretion Nutraveda has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.45, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accretion Nutraveda's current EBITDA Margin % of 18.81% is 51.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Accretion Nutraveda and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Nutraveda's current EBITDA Margin % is 18.81%, which is 24% below median its own 10-year median of 24.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Nutraveda stock overvalued right now?
Accretion Nutraveda (BOM:544694) has a current EBITDA Margin % of 18.81%. The current EBITDA Margin % is 18.81%, which is 24% below median its 10-year median of 24.74 and 51.1% above the Drug Manufacturers industry median of 12.45. Accretion Nutraveda's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Accretion Nutraveda (BOM:544694), the current EBITDA Margin % is 18.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Nutraveda Ltd is engaged in the business of the Manufacturing of Ayurvedic and Nutraceutical products across several dosage forms, including Tablets, Capsules, Oral liquids, Oral Powders, External Preparation and Oils. It is a healthcare focused Company specializing in contract manufacturing, serving domestic as well as export markets in various countries like Sri Lanka, Singapore and the USA. The company offers a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science. Its product portfolio includes Tablets, such as film-coated and chewable varieties, for applications in liver care, gynecological care, bone and joint health, and respiratory support.
21GF Score
Get the complete analysis for BOM:544694
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544694 has been successfully added to your 
